Latest Listing Rules News

Southern Cross Electrical Engineering (ASX:SXE) has launched a non-underwritten Share Purchase Plan targeting up to $15 million at $4.00 per share, matching its recent institutional placement price. The raise aims to support working capital for new projects and provide flexibility for future acquisitions.

Findi Limited has voluntarily suspended trading of its shares pending an announcement on its ongoing strategic review and financing discussions, delaying the FY26 audited financial statements beyond the June 30 deadline.

Hawk Resources Limited has had its HWKOB securities suspended from trading pending compliance with ASX Listing Rule 2.5, affecting only this class of securities.

Ballymore Resources has secured $5.2 million through an oversubscribed capital raise, boosting its capacity to fast-track exploration across multiple Queensland projects.

Dotz Nano has secured A$3.3 million through a private placement, backing its next phase of production scale-up and customer engagement under incoming CEO Nati Harpaz.

Alligator Energy has secured a crucial option to acquire a lease enabling expanded exploration at its Samphire Project while addressing ASX concerns over recent trading linked to a Mineral Resource Estimate update.

BOA Resources Ltd has voluntarily suspended trading of its shares on the ASX pending a potential acquisition announcement, with the suspension expected to last up to five trading days.

NoviqTech Limited has clarified that its planned divestment of Non-Coralia assets was not foreseen during its Coralia acquisition and reflects a strategic pivot to biochar carbon removal, with leadership changes aligned to this refocus.

INOVIQ Limited confirms no undisclosed price-sensitive information amid recent share price surge, attributing the move to external research spotlighting upcoming EXO-OC ovarian cancer test data.

Novonix has secured A$20.7 million from an institutional placement at a 33% discount, alongside a A$3 million Share Purchase Plan for existing shareholders, aiming to fund production capacity expansion amid growing battery demand.

LTR Pharma has confirmed it disclosed a binding US commercialisation agreement for ROXUS promptly after signing, responding to ASX scrutiny over pre-announcement trading activity.

PathKey.AI (ASX:PKY) confirmed no undisclosed price-sensitive information amid a recent jump in its share price and trading volume, attributing the move to prior announcements and investor interest in AI opportunities.